PRES in the Setting of Mycophenolate Use for Lupus Nephritis: A Diagnostic Challenge with Therapeutic Implications

Puntos clave

• Mycophenolate use may lead to posterior reversible encephalopathy syndrome (PRES) in lupus nephritis patients, complicating diagnosis.
• The study identifies PRES as a critical diagnostic challenge, impacting the management of lupus nephritis patients treated with mycophenolate.
• Assessment involved clinical observations and imaging studies to evaluate the relationship between mycophenolate and PRES symptoms.
• These findings underscore the need for heightened awareness of PRES in lupus nephritis treatment protocols, especially when using mycophenolate.